(ARTO trial-NCT03449719): Role of local treatment after progression in patients with castrate-resistant prostate cancer undergoing first-line abiraterone treatment.

被引：0

作者：

Francolini, Giulio

Di Cataldo, Vanessa

Detti, Beatrice

Garlatti, Pietro

Caini, Saverio

Bruni, Alessio

Ingrosso, Gianluca

D'Angelillo, Rolando Maria

Alitto, Anna Rita

Augugliaro, Matteo

Triggiani, Luca

Parisi, Silvana

Facchini, Gaetano

Banini, Marco

Simontacchi, Gabriele

Desideri, Isacco

Meattini, Icro

Valicenti, Richard K.

Livi, Lorenzo

机构：

[1] Univ Florence, Radiat Oncol Unit, Azienda Osped Univ Careggi, Florence, Italy

[2] Univ Florence, Dept Biomed Expt & Clin Sci Mario Serio, Florence, Italy

[3] Inst Canc Res Prevent & Clin Network, Canc Risk Factors & Life Style Epidemiol Unit, Florence, Italy

[4] Univ Hosp Modena, Dept Oncol & Hematol, Radiotherapy Unit, Modena, Italy

[5] Univ Perugia, Radiat Oncol Sect, Dept Med & Surg, Perugia, Italy

[6] Univ Roma Tor Vergata, Radiat Oncol, Dept Biomed & Prevent, Rome, Italy

[7] Fdn Policlin Univ A Gemelli IRCCS, UOC Radioterapia Oncol, Dipartimento Diagnost Immagini Radioterapia Oncol, Rome, Italy

[8] Azienda USL IRCCS Reggio Emilia, Unit Radiotherapy, Reggio Emilia, Italy

[9] Univ Brescia, Dept Radiat Oncol, Brescia, Italy

[10] Univ Messina, Radiat Oncol Unit, Dept Biomed Dent Sci & Morphol & Funct Images, Messina, Italy

[11] SM Grazie Hosp, Med Oncol Unit, Naples, Italy

[12] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期

关键词：

261-137-3222-3876-5567; 130-540-543-12277-2683; 261-265; 261-566-11347; 3282-270-434-2806; 283-2494-5577-2829; 7; 5; 3; 2; 162; 175; 3617; 1;

D O I：

10.1200/JCO.2024.42.4_suppl.130

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：130 / 130

页数：1

共 50 条

[31] Risk factors for progression or death in ovarian cancer patients who completed first-line platinum treatment.
Westin, Shannon Neville
Louie-Gao, Melinda
Badamgarav, Enkhe
Bala, Mohan V.
Thaker, Premal H.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[32] Early response assessment in 18F-choline PET/CT for patients with castrate-resistant metastatic prostate cancer after one-month treatment with acetate abiraterone
Boughdad, S.
Le Moulec, S.
Massard, C.
Farace, F.
Vielh, P.
Aupee, O.
Metivier, D.
Vedrine, L.
Gontier, E.
MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2015, 39 (04): : 386 - 395
[33] Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment
Boerrigter, Emmy
Benoist, Guillemette E.
van Oort, Inge M.
Verhaegh, Gerald W.
van Hooij, Onno
Groen, Levi
Smit, Frank
Oving, Irma M.
de Mol, Pieter
Smilde, Tineke J.
Somford, Diederik M.
Mehra, Niven
Schalken, Jack A.
van Erp, Nielka P.
MOLECULAR ONCOLOGY, 2021, 15 (09) : 2453 - 2465
[34] Final results from the randomized CABADOC trial: Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC).
Baciarello, Giulia
Delva, Remy
Gravis, Gwenaelle
Tazi, Youssef
Theodore, Christine
Gross-Goupil, Marine
Bompas, Emmanuelle
Joly, Florence
Lharidon, Tifenn
Thierry Nguyen Tan Hon
Barthelemy, Philippe
Culine, Stephane
Berdah, Jean Francois
Deblock, Mathilde
Beuzeboc, Philippe
Flechon, Aude
Cheneau, Caroline
Martineau, Geraldine
Borget, Isabelle
Fizazi, Karim
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[35] Reduced Dose of Abiraterone Acetate with Concomitant Low-dose Prednisone in the Treatment of ≥85 Year-old Patients with Advanced Castrate-resistant Prostate Cancer
Petrioli, Roberto
Francini, Edoardo
Fiaschi, Anna Ida
Laera, Letizia
Miano, Salvatora Tindara
De Rubertis, Giovanni
Roviello, Giandomenico
ANTICANCER RESEARCH, 2015, 35 (05) : 3097 - 3102
[36] Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial
Roy, Soumyajit
Sun, Yilun
Morgan, Scott C.
Wallis, Christopher J. D.
King, Kevin
Zhou, Yu M.
D'souza, Leah A.
Azem, Omar
Cueto-Marquez, Adrianna E.
Camden, Nathaniel B.
Spratt, Daniel E.
Kishan, Amar U.
Saad, Fred
Malone, Shawn
EUROPEAN UROLOGY, 2023, 83 (06) : 571 - 579
[37] Clinical benefit of docetaxel or enzalutamide after progression on first-line abiraterone acetate and prednisone in men with metastatic castration resistant prostate cancer (mCRPC)
Zhang, Tian
Dhawan, Mellika S.
Healy, Patrick
George, Daniel J.
Olden, Jorge
Chin, Bennett
Armstrong, Andrew J.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[38] Real-world outcomes of abiraterone and enzalutamide in first-line treatment of metastatic castration-resistant prostate cancer: which patients benefit most?
Garcia Trevijano Cabetas, Macarena
Escario-Gomez, Miguel
Gonzalez-Del Valle, Luis
Sobrino Jimenez, Carmen
Bilbao Gomez-Martino, Cristina
Romero-Garrido, Jose Antonio
Benedi-Gonzalez, Juana
Espinosa Arranz, Enrique
Diaz Almiron, Mariana
Herrero Ambrosio, Alicia
EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2023, 30 (05) : 268 - 272
[39] Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients
Caffo, Orazio
Lo Re, Giovanni
Sava, Teodoro
Buti, Sebastiano
Sacco, Cosimo
Basso, Umberto
Zustovich, Fable
Lodde, Michele
Perin, Alessandra
Facchini, Gaetano
Veccia, Antonello
Maines, Francesca
Barile, Carmen
Fratino, Lucia
Gernone, Angela
De Vivo, Rocco
Pappagallo, Giovanni L.
Galligioni, Enzo
FUTURE ONCOLOGY, 2015, 11 (06) : 965 - 973
[40] Survival outcome in patients with metastatic castration-resistant prostate cancer according to first-line treatment
Thurin, Nicolas H.
Rouyer, Magali
Jove, Jeremy
Gross-Goupil, Marine
Haaser, Thibaud
Rebillard, Xavier
Soulie, Michel
de Pouvourville, Gerard
Pierres, Marie
Capone, Camille
Lamarque, Stephanie
Bignon, Emmanuelle
Droz-Perroteau, Cecile
Moore, Nicholas
Blin, Patrick
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 114 - 114

← 1 2 3 4 5 →